The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2
Torrente, L.; Maan, G.; Casares, L.; Jackson, A.; Honda, T.; Wells, G.; Kulesskiy, E.; Saarela, J.; Dinkova-Kostova, A. T.; de la Vega, L.
Show abstract
Aberrant hyperactivation of NRF2 is a common event in many tumour types and associates with resistance to therapy and poor patient prognosis. The identification of ways to overcome the protection provided by NRF2 and selectively kill cancer cells addicted to NRF2 is a desirable goal. Exploiting the CRISPR/Cas9 technology, we generated colorectal cancer cell lines with hyperactive NRF2, and used them to perform a drug screen. We identified AT9283, an Aurora kinase inhibitor, for its selectivity towards killing cancer cells with hyperactive NRF2 as a consequence to either genetic or pharmacological activation. Our results show that hyperactivation of NRF2 presents a potential vulnerability that could be therapeutically exploited, and further suggest that AT9283, a drug that is currently in clinical trials, holds promise for the treatment of tumours with hyperactive NRF2.\n\nHighlightsO_LIWe present a new model for NRF2 hyperactivation in colorectal cancer cells.\nC_LIO_LIAT9283 selectively kills cancer cells with hyperactive NRF2\nC_LIO_LIBoth genetic and pharmacological activation of NRF2 sensitise cells to AT9283\nC_LI
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Chemical, physical and biological triggers of Bcl-xL-mediated apoptosis 94%
- Synthetic lethality screening identifies FDA-approved drugs that overcome ATP7B-mediated tolerance of tumor cells to cisplatin 94%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 94%
Similar papers in this journal
- Discovery of a AhR flavonoid agonist that counter-regulates ACE2 expression in rodent models of inflammation and attenuates ACE2-SARS-CoV2 interaction in vitro 94%
- Ribosomal protein L5 (RPL5/uL18) I60V mutation is associated to increased translation and modulates drug sensitivity in T-cell acute lymphoblastic leukemia cells 93%
- Mitophagy contributes to alpha-tocopheryl succinate toxicity in GSNOR-deficient hepatocellular carcinoma. 93%
Similar papers in this journal
- Identification of a cardiac glycoside exhibiting favorable brain bioavailability and potency for reducing levels of the cellular prion protein 94%
- Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19 94%
- The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification 93%
Similar papers in this journal
- NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity. 95%
- Novel assays monitoring direct glucocorticoid receptor protein activity exhibit high predictive power for ligand activity on endogenous gene targets 94%
- Characterization of new highly selective pyrazolopyrimidine inhibitor of CDK7 94%
Similar papers in this journal
- Chemogenomic screening Identifies the Hsp70 Co-chaperone HDJ2 as a Hub for Anticancer Drug Resistance 95%
- The molecular basis of the anticancer effect of statins 94%
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.